Etoposide: four decades of development of a topoisomerase II inhibitor

Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II

1984 • 1,477 citations

DNA gyrase: an enzyme that introduces superhelical turns into DNA.

1976 • 1,175 citations

Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response

1977 • 1,116 citations

Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy

1991 • 934 citations

Interaction between DNA and an Escherichia coli protein ω

1971 • 749 citations

Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia

1991 • 723 citations

DNA Topoisomerases: Essential Enzymes and Lethal Targets

1994 • 722 citations

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1997 • 628 citations

Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism

1995 • 501 citations

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

1989 • 467 citations

Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.

1988 • 415 citations

Idarubicin

1991 • 340 citations

The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture.

1991 • 279 citations

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial

1996 • 226 citations

DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

1983 • 223 citations

Mitoxantrone

1991 • 208 citations

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1976 • 187 citations

Rationale for the use of mitoxantrone in the older patient: cardiac toxicity.

1995 • 184 citations

Antitopoisomerase drug action and resistance

1996 • 176 citations

Topoisomerase Inhibitors

1995 • 173 citations

Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.

1984 • 149 citations

Bioavailability of low-dose oral etoposide.

1993 • 147 citations

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

1979 • 142 citations

Inhibition of intestinal P-glycoprotein and effects on etoposide absorption

1995 • 138 citations

The clinical pharmacology of etoposide

1991 • 136 citations

Mitoxantrone: an overview of safety and toxicity

1985 • 122 citations

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.

1994 • 117 citations

The Similarity of the Effect of Podophyllin and Colchicine and Their Use in the Treatment of Condylomata Acuminata

1946 • 114 citations

Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.

1986 • 109 citations

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.

1995 • 106 citations

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma

1996 • 103 citations

Predicting etoposide toxicity: relationship to organ function and protein binding.

1996 • 102 citations

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.

1976 • 102 citations

Helicase inhibition by anthracycline anticancer agents.

1992 • 99 citations

Etoposide phosphate: what, why, where, and how?

1996 • 98 citations

Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.

1990 • 81 citations

VP-16-213 (etoposide): The mandrake root from Issyk-Kul

1982 • 79 citations

Randomized Trial of Doxorubicin, Bisantrene, and Miltoxantrone in Advanced Breast Cancer: A Southwest Oncology Group Study

1991 • 73 citations

Etoposide kinetics in patients with obstructive jaundice.

1990 • 70 citations

Etoposide: an update.

1989 • 66 citations

EPEG, a new antineoplastic epipodophyllotoxin

1975 • 64 citations

In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy

1987 • 63 citations

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.

1993 • 60 citations

Current status of etoposide in the management of small cell lung cancer

1991 • 51 citations

Damage Induced in Sarcoma 37 with Podophyllin, Podophyllotoxin Alpha-Peltatin, Beta-Peltatin, and Quercetin<xref ref-type="fn" rid="fn1"><sup>2</sup></xref>

1950 • 50 citations

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.

1997 • 50 citations

Adriamycin-dependent release of iron from microsomal membranes

1989 • 49 citations

Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.

1994 • 49 citations

Etoposide. Current and future status

1991 • 47 citations

Effect of Alpha-Peltatin, Beta-Peltatin, and Podophyllotoxin on Lymphomas and Other Transplanted Tumors<xref ref-type="fn" rid="fn1"><sup>2</sup></xref>

1950 • 41 citations

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.

1995 • 38 citations

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from the Children's Cancer Group

1996 • 36 citations

PTG, a new antineoplastic epipodophyllotoxin

1975 • 36 citations

Pharmacological attempts to improve the bioavailability of oral etoposide

1995 • 34 citations

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

1996 • 34 citations

The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example

1996 • 32 citations

Etoposide pharmacology.

1992 • 31 citations

Etoposide in the management of metastatic breast cancer

1991 • 30 citations

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.

1996 • 30 citations

Current strategies in the management of locoregional and metastatic gastric carcinoma

1991 • 28 citations

Phase I clinical and pharmacokinetic study of oral etoposide phosphate.

1995 • 28 citations

A review of idarubicin in acute leukemia.

1993 • 27 citations

Review of current clinical experience with prolonged (oral) etoposide in cancer treatment.

1995 • 26 citations

Measurements of In Vivo Megakaryocytopoiesis: Studies in Nonhuman Primates and Patients

1996 • 25 citations

Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer.

1995 • 24 citations

A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days*

1995 • 23 citations

New chemotherapies for ovarian cancer. Systemic and intraperitoneal podophyllotoxins

1991 • 20 citations

Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors

1996 • 17 citations

Potential Role of Oral Anthracyclines in Older Patients with Cancer

1994 • 17 citations

Pharmacodynamic modeling of prolonged administration of etoposide

1996 • 15 citations

Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer

1996 • 11 citations

A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.

1996 • 11 citations